Ani Pharmaceuticals Share Price (NASDAQ: ANIP)

$93.5

▲

0.97

(1.05%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Ani Pharmaceuticals Stock chart to analyse performance

Ani Pharmaceuticals stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$92.66
Today's High:$93.63
$93.50
0.9%
Downside
Day's Volatility :1.04%
Upside
0.14%
52 Weeks Low:$52.50
52 Weeks High:$93.63
$93.50
43.85%
Downside
52 Weeks Volatility :43.93%
Upside
0.14%

Ani Pharmaceuticals Stock Returns

Period	Ani Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	51.1%	3.6%	0.0%
6 Months	60.02%	-7.7%	0.0%
1 Year	48.41%	-12.6%	0.0%
3 Years	152.82%	9.5%	-4.7%

Ani Pharmaceuticals Inc Key Stats

Check Ani Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$92.53
Open	$93.14
Today's High	$93.63
Today's Low	$92.66
Market Capitalization	$2.0B
Today's Volume	$283.2K
52 Week High	$93.63
52 Week Low	$52.5
Revenue TTM	$747.4M
EBITDA	$104.3M
Earnings Per Share (EPS)	$-0.69
Profit Margin	-1.37%
Quarterly Earnings Growth YOY	-0.17%
Return On Equity TTM	-2.17%

Stock Returns calculator for Ani Pharmaceuticals Stock including INR - Dollar returns

The Ani Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Ani Pharmaceuticals investment value today

Current value as on today

₹1,51,951

Returns

₹51,951

(+51.95%)

Returns from Ani Pharmaceuticals Stock

₹46,667 (+46.67%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Ani Pharmaceuticals Stock

71%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Ani Pharmaceuticals Stock from India on INDmoney has increased by 71% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Ani Pharmaceuticals Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
12.19%
Vanguard Group Inc
5.88%
Global Alpha Capital Management Ltd.
3.97%
Millennium Management LLC
3.77%
Citadel Advisors Llc
3.33%
State Street Corp
3.29%

Analyst Recommendation on Ani Pharmaceuticals Stock

Rating

Trend

Buy

90%Buy

9%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Ani Pharmaceuticals(by analysts ranked 0 to 5 stars)

Ani Pharmaceuticals Share Price Target

What analysts predicted

Upside of 2.14%

Target:

$95.50

Current:

$93.50

Ani Pharmaceuticals share price target is $95.50, a slight Upside of 2.14% compared to current price of $93.50 as per analysts' prediction.

Ani Pharmaceuticals Stock Insights

Price Movement
In the last 1 month, ANIP stock has moved up by 46.1%
Increasing Revenue
Revenue is up for the last 7 quarters, 131.65M → 211.37M (in $), with an average increase of 7.3% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 15.68M → 7.73M (in $), with an average decrease of 50.7% per quarter

Ani Pharmaceuticals Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$206.5M	↑ 2.47%
Net Income	$6.1M	↓ 60.67%
Net Profit Margin	2.95%	↓ 4.74%

	FY20	Y/Y Change
Revenue	$208.5M	↑ 0.93%
Net Income	$-22.5M	↓ 470.0%
Net Profit Margin	-10.82%	↓ 13.77%

	FY21	Y/Y Change
Revenue	$216.1M	↑ 3.67%
Net Income	$-42.6M	↑ 88.94%
Net Profit Margin	-19.71%	↓ 8.89%

	FY22	Y/Y Change
Revenue	$316.4M	↑ 46.38%
Net Income	$-47.9M	↑ 12.42%
Net Profit Margin	-15.14%	↑ 4.57%

	FY23	Y/Y Change
Revenue	$486.8M	↑ 53.87%
Net Income	$18.8M	↓ 139.21%
Net Profit Margin	3.86%	↑ 19.0%

	FY24	Y/Y Change
Revenue	$614.4M	↑ 26.2%
Net Income	$-18.5M	↓ 198.63%
Net Profit Margin	-3.01%	↓ 6.87%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$137.4M	↑ 4.39%
Net Income	$18.2M	↑ 1476.36%
Net Profit Margin	13.25%	↑ 12.37%

	Q2 FY24	Q/Q Change
Revenue	$138.0M	↑ 0.44%
Net Income	$-2.3M	↓ 112.56%
Net Profit Margin	-1.66%	↓ 14.91%

	Q3 FY24	Q/Q Change
Revenue	$148.3M	↑ 7.46%
Net Income	$-24.2M	↑ 956.67%
Net Profit Margin	-16.29%	↓ 14.63%

	Q4 FY24	Q/Q Change
Revenue	$190.6M	↑ 28.48%
Net Income	$-10.3M	↓ 57.48%
Net Profit Margin	-5.39%	↑ 10.9%

	Q1 FY25	Q/Q Change
Revenue	$197.1M	↑ 3.44%
Net Income	$15.7M	↓ 252.6%
Net Profit Margin	7.95%	↑ 13.34%

	Q2 FY25	Q/Q Change
Revenue	$211.4M	↑ 7.23%
Net Income	$7.7M	↓ 50.7%
Net Profit Margin	3.66%	↓ 4.29%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$143.4M	↑ 11.54%

	FY20	Y/Y Change
Profit	$121.3M	↓ 15.39%

	FY21	Y/Y Change
Profit	$115.5M	↓ 4.77%

	FY22	Y/Y Change
Profit	$177.6M	↑ 53.73%

	FY23	Y/Y Change
Profit	$305.3M	↑ 71.9%

	FY24	Y/Y Change
Profit	$364.2M	↑ 19.28%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$73.6M	↑ 16.73%

	Q2 FY24	Q/Q Change
Profit	$65.6M	↓ 10.79%

	Q3 FY24	Q/Q Change
Profit	$85.3M	↑ 29.88%

	Q4 FY24	Q/Q Change
Profit	$110.3M	↑ 29.37%

	Q1 FY25	Q/Q Change
Profit	$124.1M	↑ 12.5%

	Q2 FY25	Q/Q Change
Profit	$113.5M	↓ 8.55%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$45.6M	↓ 31.97%
Investing Cash Flow	$-27.5M	↑ 0.62%
Financing Cash Flow	$1.3M	↓ 104.49%

	FY20	Y/Y Change
Operating Cash Flow	$15.3M	↓ 66.54%
Investing Cash Flow	$-68.3M	↑ 148.0%
Financing Cash Flow	$-1.4M	↓ 215.12%

	FY21	Y/Y Change
Operating Cash Flow	$3.3M	↓ 78.24%
Investing Cash Flow	$-105.5M	↑ 54.39%
Financing Cash Flow	$194.6M	↓ 13622.93%

	FY22	Y/Y Change
Operating Cash Flow	$-31.2M	↓ 1039.28%
Investing Cash Flow	$-15.7M	↓ 85.08%
Financing Cash Flow	$-5.1M	↓ 102.63%

	FY23	Y/Y Change
Operating Cash Flow	$119.0M	↓ 481.24%
Investing Cash Flow	$-18.5M	↑ 17.62%
Financing Cash Flow	$67.4M	↓ 1415.63%

	FY24	Y/Y Change
Operating Cash Flow	$64.0M	↓ 46.19%
Investing Cash Flow	$-404.7M	↑ 2086.37%
Financing Cash Flow	$264.9M	↑ 292.87%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$18.3M	↓ 59.17%
Investing Cash Flow	$8.9M	↓ 286.92%
Financing Cash Flow	$-19.7M	↑ 65.51%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$17.4M	↓ 4.68%
Investing Cash Flow	$-4.4M	↓ 149.8%
Financing Cash Flow	$-1.5M	↓ 92.64%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$12.5M	↓ 28.37%
Investing Cash Flow	$-398.5M	↑ 8857.56%
Financing Cash Flow	$291.0M	↓ 20143.39%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$15.9M	↑ 27.14%
Investing Cash Flow	$-10.7M	↓ 97.32%
Financing Cash Flow	$-4.9M	↓ 101.69%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$35.0M	↑ 120.62%
Investing Cash Flow	$-19.8M	↑ 85.81%
Financing Cash Flow	$-9.9M	↑ 101.87%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$75.8M	↑ 116.66%
Investing Cash Flow	$-6.9M	↓ 65.19%
Financing Cash Flow	$-1.7M	↓ 82.36%

Ani Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Ani Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Ani Pharmaceuticals Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ani Pharmaceuticals Inc	47.66%	60.02%	48.41%	152.82%	206.1%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ani Pharmaceuticals Inc	49.06	NA	1.06	7.23	-0.02	0.01	NA	21.7
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ani Pharmaceuticals Inc	Buy	$2.0B	206.1%	49.06	-1.37%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Ani Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Organization	Ani Pharmaceuticals
Employees	897
CEO	Mr. Nikhil Lalwani
Industry	Health Technology

Key Management of Ani Pharmaceuticals Inc

Name	Title
Mr. Nikhil Lalwani	President, CEO & Director
Mr. Stephen P. Carey	Senior VP of Finance & CFO
Ms. Meredith W. Cook J.D.	Senior VP, General Counsel & Corporate Secretary
Mr. Christopher K. Mutz	Senior VP & Head of Rare Disease
Mr. Ori Gutwerg	Senior Vice President of Generics
Mr. Muthusamy Shanmugam MS R.Ph.	Head of R&D, COO of New Jersey Operations & Director
Ms. Elizabeth Powell J.D.	Chief Compliance Officer & Head of Legal of Rare Disease
Mr. Chad Gassert	Senior Vice President of Corporate Development & Strategy
Ms. Krista L. Davis	Senior VP & Chief Human Resources Officer
Dr. Mary Pao M.D., Ph.D.	Chief Medical Officer

Important FAQs about investing in ANIP Stock from India :

What is Ani Pharmaceuticals share price today?

Ani Pharmaceuticals share price today is $93.50 as on August 30, 2025 at 1:29 am IST at the close of the market. Ani Pharmaceuticals share today touched a day high of $93.63 and a low of $92.66.

What is the 52 week high and 52 week low for Ani Pharmaceuticals share?

Ani Pharmaceuticals share touched a 52 week high of $93.63 and a 52 week low of $52.50. Ani Pharmaceuticals stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $93.50, lower by 0.14% versus the 52 week high.

How to invest in Ani Pharmaceuticals Stock (ANIP) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Ani Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ani Pharmaceuticals Shares that will get you 0.0160 shares as per Ani Pharmaceuticals share price of $93.50 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Ani Pharmaceuticals Stock (ANIP) from India?

Indian investors can start investing in Ani Pharmaceuticals (ANIP) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Ani Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Ani Pharmaceuticals share’s latest price of $93.50 as on August 30, 2025 at 1:29 am IST, you will get 0.1070 shares of Ani Pharmaceuticals. Learn more about fractional shares .

What are the returns that Ani Pharmaceuticals has given to Indian investors in the last 5 years?

Ani Pharmaceuticals stock has given 206.1% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?